With strong ties to Cornell, from which Rheonix Inc has licensed several technology platforms, Rheonix is exploiting its novel patented microfluidic chip technology to develop automated molecular diagnostic platforms products that address some of the most pressing issues in global healthcare today, including Avian Influenza, AIDS, SARS, bioterrorism, affordable healthcare in developing countries, personalized medicine, molecular biology, etc. The firm effectively operates as a biomedical device company with products including CARD (Chemistry And Reagent Device) systems to miniaturize and automate new and existing assays in multiple fields. The firm's products and technology are used in a range of settings: human/veterinary in vitro diagnostics, food/water testing, SNP analysis for personalized medicine applications, homeland security/defense applications, process control and final product QC, and tissue culture analysis in a research or production setting. Different IP portfolios, grown by self-funded and Federal grants, are available for sub-licensing; these include several sensitive liposome-based biosensor platforms, such as lateral flow and microfluidic/electrochemical. In addition, an exquisitely sensitive, resonating mechanical biosensor platform, capable of detecting single microbes or single DNA molecules is also available. Finally, the firm develops unique MEMS and NEMS technology, resonating structures with applications in the telecommunications industry, including RFID; these are also available for sub-licensing. The firm's EncompassMDx platform is a customizable molecular diagnostic system that operates interchangeable purification, amplification, and detection modules organized on single-use cartridges.
